Cornercap Investment Counsel’s Catalyst Pharmaceutical CPRX Stock Holding History

Cornercap Investment Counsel’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,683	Closed	-$494K	–	220
2024 Q4	$494K	Buy	+23,683	New	+$509K	0.16%	218
2024 Q2	–	Sell	-12,216	Closed	-$195K	–	615
2024 Q1	$195K	Sell	12,216 -1,171	-9%	-$17.6K	0.03%	569
2023 Q4	$225K	Sell	13,387 -73,786	-85%	-$1.01M	0.04%	517
2023 Q3	$1.02M	Buy	87,173 +30,938	+55%	+$414K	0.19%	169
2023 Q2	$756K	Hold	56,235	–	–	0.13%	330
2023 Q1	$932K	Sell	56,235 -17,183	-23%	-$283K	0.16%	261
2022 Q4	$1.37M	Sell	73,418 -9,517	-11%	-$147K	0.24%	108
2022 Q3	$1.06M	Sell	82,935 -67,124	-45%	-$796K	0.2%	146
2022 Q2	$1.05M	Buy	150,059 +2,643	+2%	+$19.4K	0.18%	184
2022 Q1	$1.22M	Sell	147,416 -10,786	-7%	-$76.3K	0.14%	198
2021 Q4	$1.07M	Sell	158,202 -57,942	-27%	-$381K	0.15%	265
2021 Q3	$1.15M	Buy	+216,144	New	+$1.18M	0.13%	262

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Cornercap Investment Counsel's CPRX Position: Q1 2025 in Review

Cornercap Investment Counsel sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 23,683 shares — an estimated $494K sold.

Cornercap Investment Counsel first reported a position in CPRX in Q3 2021 and held it in 12 quarters. The position peaked at $1.37M in Q4 2022. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

Cornercap Investment Counsel reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Cornercap Investment Counsel sold 23,683 Catalyst Pharmaceutical shares in Q1 2025, an estimated $494K.
Cornercap Investment Counsel first reported a position in Catalyst Pharmaceutical in Q3 2021 and held it in 12 quarters.
Cornercap Investment Counsel's Catalyst Pharmaceutical position peaked at $1.37M in Q4 2022.
371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Cornercap Investment Counsel's 13F filing for Q1 2025, filed 2 May 2025.